Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Treasury Shares (2021 - 2025)

Aligos Therapeutics' Treasury Shares history spans 5 years, with the latest figure at $76786.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 1523.73% year-over-year to $76786.0; the TTM value through Dec 2025 reached $76786.0, up 1523.73%, while the annual FY2025 figure was $76786.0, 1523.73% up from the prior year.
  • Treasury Shares reached $76786.0 in Q4 2025 per ALGS's latest filing, roughly flat from $76861.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $303711.0 in Q1 2021 to a low of $3717.0 in Q2 2022.
  • Average Treasury Shares over 5 years is $90332.0, with a median of $76823.5 recorded in 2025.
  • Peak YoY movement for Treasury Shares: plummeted 98.35% in 2022, then surged 1635.4% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $89054.0 in 2021, then tumbled by 95.83% to $3717.0 in 2022, then skyrocketed by 44.26% to $5362.0 in 2023, then fell by 11.81% to $4729.0 in 2024, then skyrocketed by 1523.73% to $76786.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Treasury Shares are $76786.0 (Q4 2025), $76861.0 (Q3 2025), and $17264.0 (Q2 2025).